Email updates

Keep up to date with the latest news and content from AACI and BioMed Central.

Open Access Highly Accessed Case report

Long-term benefits of omalizumab in a patient with severe non-allergic asthma

Francesco Menzella*, Roberto Piro, Nicola Facciolongo, Claudia Castagnetti, Anna Simonazzi and Luigi Zucchi

Author Affiliations

Department of Respiratory Diseases, Santa Maria Nuova Hospital, Reggio, Emilia, Italy

For all author emails, please log on.

Allergy, Asthma & Clinical Immunology 2011, 7:9  doi:10.1186/1710-1492-7-9

Published: 24 May 2011

Abstract

Introduction

Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.

Case presentation

We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.

Conclusion

Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.